ARTEMIDE-HCC01 is a randomized, open-label, sponsor-blinded, multicenter phase III study evaluating rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line treatment in patients with advanced hepatocellular carcinoma. The primary objective is to assess efficacy, including progression-free survival (PFS) and overall survival (OS). Eligible patients are adults with unresectable or metastatic HCC who have not received prior systemic therapy. Participants are randomized to receive different combination regimens. Safety and tolerability are also evaluated. Key secondary endpoints include additional efficacy measures and patient-reported outcomes.
This study is testing a new combination of cancer medicines in patients with advanced liver cancer. It evaluates whether rilvegostomig together with bevacizumab, with or without another drug called tremelimumab, works as a first-line treatment. The goal is to find out if the treatment can slow down disease progression and how well it is tolerated. Adults with liver cancer that cannot be removed by surgery or has spread, and who have not received prior systemic therapy, can take part. Participants are randomly assigned to different treatment groups. The study also looks at survival outcomes and quality of life.
